Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drug Safety

• Publication date

  2012-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/11631330-000000000-00000PMID 23061737
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prescription–Event Monitoring

  2012cited by this paper
• Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer

  2011cited by this paper
• Modified Prescription-Event Monitoring Studies

  2011cited by this paper
• Risk of Depressive Episodes with Rimonabant

  2011cited by this paper
• Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications.

  2010cited by this paper
• Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications

  2010cited by this paper
• The endocannabinoid system and psychiatric disorders.

  2010cited by this paper
• Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti‐obesity drugs

  2009cited by this paper
• Two Pharmacy Interventions to Improve Refill Persistence for Chronic Disease Medications: A Randomized, Controlled Trial

  2009cited by this paper
• Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss.

  2009cited by this paper
• Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.

  2008cited by this paper
• Characteristics and Reasons Associated with Nonacceptance of Selective Serotonin-Reuptake Inhibitor Treatment

  2008cited by this paper
• The hope and fear of rimonabant.

  2008cited by this paper
• Depression and Diabetes Treatment Nonadherence: A Meta-Analysis

  2008cited by this paper
• Psychiatric and Cardiovascular Comorbidities in Patients With Diabetes Mellitus Starting Antiobesity Drugs

  2008cited by this paper
• Hypertenion: Sensitivity of Patient Outcomes to Pharmacist Interventions. Part II: Systematic Review and Meta-Analysis in Hypertension Management

  2007cited by this paper
• The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas.

  2007cited by this paper
• Sensitivity of Patient Outcomes to Pharmacist Interventions. Part I: Systematic Review and Meta-Analysis in Diabetes Management

  2007cited by this paper
• Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.

  2006cited by this paper
• Under-Reporting of Adverse Drug Reactions

  2006cited by this paper
• Mechanisms linking obesity to insulin resistance and type 2 diabetes

  2006cited by this paper
• Effectiveness of Interventions by Community Pharmacists to Improve Patient Adherence to Chronic Medication: A Systematic Review

  2005cited by this paper
• Rate and determinants of 10-year persistence with antihypertensive drugs

  2005cited by this paper
• Reasons for switching between antipsychotics in daily clinical practice.

  2005cited by this paper
• Long term persistence with statin treatment in daily medical practice

  2004cited by this paper
• Persistence with inhaled corticosteroid therapy in daily practice.

  2004cited by this paper
• Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors.

  2004cited by this paper
• Clinical interventions for treatment non-adherence in psychosis: Meta-analysis

  2003cited by this paper
• Interventions to improve medication adherence in schizophrenia.

  2002cited by this paper
• Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study

  1998cited by this paper
• General practice postal surveys: a questionnaire too far?

  1996cited by this paper
• PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Evaluation of patients ’ experiences with antidepressants reported by means of a medicine reporting system

  year unknowncited by this paper

• Pharmacotherapy of obesity: an update.

  2021cites this paper
• The Cannabinoid CB1 Receptor in Schizophrenia.

  2020cites this paper
• Use of the forced swim test to assess “despair”

  2019cites this paper
• Intensive Monitoring Studies for Assessing Medicines: A Systematic Review

  2019cites this paper
• Contribution of UK Prescription-Based Event Monitoring Methods in the Pharmacovigilance of Psychotropic Medications

  2016cites this paper
• NESS06SM reduces body weight with an improved profile relative to SR141716A.

  2013cites this paper
• Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol

  2013cites this paper
• Las lipoproteínas de alta densidad: protectoras vasculares contra la aterosclerosis

  2013cites this paper